Literature DB >> 25113745

Chikungunya virus was isolated in Thailand, 2010.

Mikiko Sasayama1, Surachet Benjathummarak, Norihito Kawashita, Prasert Rukmanee, Suntaree Sangmukdanun, Promsin Masrinoul, Pannamthip Pitaksajjakul, Orapim Puiprom, Pitak Wuthisen, Takeshi Kurosu, Panjaporn Chaichana, Pannamas Maneekan, Kazuyoshi Ikuta, Pongrama Ramasoota, Tamaki Okabayashi, Pratap Singhasivanon, Natthanej Luplertlop.   

Abstract

Chikungunya fever (CHIKF) is an acute febrile illness caused by a mosquito-borne alphavirus, chikungunya virus (CHIKV). This disease re-emerged in Kenya in 2004, and spread to the countries in and around the Indian Ocean. The re-emerging epidemics rapidly spread to regions like India and Southeast Asia, and it was subsequently identified in Europe in 2007, probably as a result of importation of chikungunya cases. On the one hand, chikungunya is one of the neglected diseases and has only attracted strong attention during large outbreaks. In 2008-2009, there was a major outbreak of chikungunya fever in Thailand, resulting in the highest number of infections in any country in the region. However, no update of CHIKV circulating in Thailand has been published since 2009. In this study, we examined the viral growth kinetics and sequences of the structural genes derived from CHIKV clinical isolates obtained from the serum specimens of CHIKF-suspected patients in Central Thailand in 2010. We identified the CHIKV harboring two mutations E1-A226V and E2-I211T, indicating that the East, Central, and South African lineage of CHIKV was continuously circulating as an indigenous population in Thailand.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25113745      PMCID: PMC4232745          DOI: 10.1007/s11262-014-1105-5

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


Introduction

Chikungunya virus (CHIKV; family Togaviridae; genus Alphavirus) is a mosquito-borne, single-stranded, positive-sense RNA virus that is the causative agent of chikungunya fever (CHIKF), which is a major public health problem in Africa, South America, and Southern and Southeastern Asia [1, 2]. CHIKV was first identified in Tanzania in the 1950s, and recent huge outbreak occurred in Kenya in 2004. This re-emerged epidemic subsequently spread to several countries in the Indian Ocean and India, with documented outbreak in Italy in 2007 [3]. The outbreak in New Caledonia in 2011 and the ongoing outbreak in Caribbean in 2013–2014 raise public health concerns again due to increasing number of CHIKV infections [4, 5]. There are three distinct lineages of CHIKV: the West African genotype; the East, Central, and South African (ECSA) genotype; and the Asian genotype. In Thailand, outbreaks of chikungunya were first documented in the early 1960s, and the most recent outbreak was reported in 2008–2009 [6]. Classical CHIKF is characterized by high fever, nausea, rash, and severe arthralgia; however, the clinical signs and symptoms of CHIKF are indistinguishable from those of dengue, and both illnesses are transmitted by Aedes mosquitoes, such as Ae. aegypti and Ae. albopictus [7, 8]. Studies of the clinical and molecular characteristics of CHIKV during the recent outbreak of chikungunya in Thailand indicated that the virus belonged to the ECSA genotype, which was reported in the Indian Ocean islands after 2005 [9]. These isolates harbored the E1-A226V mutation, which increases virus transmissibility via Ae. albopictus [10, 11]. By December 2009, CHIKV had spread to the Central, Northeastern, and Northern provinces of Thailand, infecting more than 46,000 individuals [1]. No study of CHIKV clinical isolates in Thailand has been published since 2009; therefore, we need to remain vigilant for the endemic situation of chikungunya in Thailand. Here, we examined the viral growth kinetics and sequences of the structural genes derived from CHIKV clinical isolates obtained from the serum specimens of CHIKF-suspected patients in Ratchaburi Province (100 km west of Bangkok) in 2010.

Results and discussion

The Royal Thai Government and the Faculty of Tropical Medicine at Mahidol University (MU-TropMed) are currently monitoring emerging diseases (e.g., dengue and malaria) with a view to future control and prevention in Ratchaburi Province. The aim of the present study was to examine the endemic situation regarding CHIKV circulation in Thailand, and in Ratchaburi Province in particular. From August to September, 2010, the MU-TropMed and Health Promoting Hospital (HPH) in Ratchaburi Province obtained 50 serum samples from individuals suspected of harboring CHIKF. Permission regarding the use of anonymous specimens was granted by the Director of HPH, and this study was approved by the Ethics Committee at MU-TropMed (MUTM 2012–047–01). Here, we report the isolation and molecular characterization of seven clinical isolates of CHIKV, which were derived from Thai individuals showing characteristic symptoms. All serum specimens were tested for CHIKV infection using the SD BIOLINE Chikungunya IgM rapid test kit (Standard Diagnostics, Kyonggi-do, Korea). Briefly, 50 µl of serum sample was dropped into the well of the test device, and assay diluent was subsequently added. Test results were interpreted at 10 min. We also performed real-time reverse transcription-PCR (RT-PCR) assay, targeting the E1 gene, using the iScript One-Step RT-PCR Kit for Probes (Bio-Rad, CA, USA). Viral RNA was extracted from 140 µl of serum sample using the QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to manufacturer’s instruction. The following primers were used for the real-time RT-PCR: CHIK-forward (AAGCTYCGCGTCCTTTACCAAG), CHIK-reverse (CCAAATTGTCCYGGTCTTCCT), and CHIK-probe (FAM-CCAATGTCYTCMGCCTGGACACCTTT-TAMRA) as described previously [12]. Of the 50 serum samples tested, 6 (12 %) were identified as CHIKV positive by real-time RT-PCR, and one (2 %) was identified as chikungunya positive by both real-time RT-PCR and Chikungunya IgM antibody test kit. All seven CHIKV-positive specimens were obtained from individuals in the acute phase of the illness (≤6 days post-onset). We isolated CHIKV using an Ae. albopictus-derived cell line, C6/36, and the supernatants of individual clinical isolates were used for further study. We first examined the viral growth kinetics of two clinical isolates (CP9 and CP11) and three control strains (Ross strain_1953, #32808_2008, and #16856_2009) selected randomly. Vero and C6/36 cells were inoculated with these viruses at a multiplicity of infection of one. The time of inoculation was set as “hour 0”. Culture supernatants were collected at 4, 8, 12, 24, and 28 h post-inoculation, and were titrated with plaque assay. The viral titers of the clinical isolates were significantly higher than those of the controls during the first 8 h post-inoculation in Vero cells (P < 0.0005) and the first 12 h post-inoculation in C6/36 cells (P < 0.005) (Supplemental Fig. 1). In Vero cells, the peak viral titers for CP9 and CP11 at 12 h post-inoculation were 3.5 × 106 and 3.6 × 106 PFU/mL, respectively. In C6/36 cells, the peak viral titers for CP9 and CP11 were 5.9 × 108 and 4.8 × 108 PFU/mL at 24 h post-inoculation, respectively. We also examined the cytopathic effects (CPEs) of CP9, CP11, and the control viruses against C6/36 cells. Both isolates showed milder CPEs in C6/36 cells than the controls. Next, to examine sequence variations within the viral genome, the seven clinical isolates were subjected to plaque purification in Vero cells. Eight plaques were selected for each of the isolates: CP1:1–8, CP7:1–8, CP9:1–8, CP10:1–8, CP11:1–8, CP13:1–8, and CP16:1–8. The region containing the structural genes (capsid–E3–E2–6k–E1) was amplified using primers published by Sreekumar et al. [13]. The amplicons were sequenced and aligned with the reference strain sequences available in GenBank (Fig. 1a). The E1-A226V and E2-I211T mutations, which provide a suitable background for CHIKV adaptation in Ae. albopictus [10, 11, 14, 15], were relatively well conserved among all clones obtained from the seven clinical isolates. Furthermore, several sequence variations were identified. We identified several unique amino acid substitutions that were not present in the strains responsible for the Thai outbreak in 2008–2009: E1-N349I in all CP16 clones; E1-P304L in clone CP7:6; E2-H131Y in clone CP13:2; and E2-E247A in clone CP16:4 (Table 1). These substitutions were conserved when compared to any strains reported in neighboring countries. Moreover, these are exposed on the surface of the molecule, suggesting that it may affect interaction of them with the other E monomers or antibodies (Fig. 1b) [16]. Phylogenetic analysis showed that all of the clinical isolates in 2010 formed a homogeneous cluster within a broad group, which also included the isolates from the Thai outbreak of 2008–2009 (ECSA genotype). Notably, all clones formed a branch that shared >99 % homology with the Indian Ocean Lineage (IOL), a relatively independent cluster within the ECSA genotype that caused an outbreak of unprecedented magnitude in 2005–2006 (Fig. 1a). This conclusion was also supported by the phylogenetic analysis based on E1 gene sequence (data not shown). The CHIKV isolates from China (2010), India (2010–2011), and Cambodia (2011) also clustered within the IOL.
Fig. 1

a Phylogenetic tree showing the relationships between the structural genes of different chikungunya virus (CHIKV) strains. The information was obtained from 56 clones derived from 7 infected patients in Ratchaburi Province of Thailand in 2010. The numbers below or above the branch nodes represent the neighbor-joining bootstrap values. Analysis was based on the nucleotide sequences of the structural genes using the MEGA 5.05 program and the maximum likelihood method based on 1,000 bootstrap replications. The 2010 isolates are denoted by black circles and bold type. Scale bars indicate 0.02 nucleotide substitutions per site. GenBank Accession numbers for all isolates were recorded. GenBank Accession nos: CP1 (AB857730–AB857737); CP7 (AB857738–AB857745); CP9 (AB857746–AB857753); CP10 (AB857754–AB857761); CP11 (AB857762–AB857769); CP13 (AB857770–AB857777); and CP16 (AB857778–AB857785), b Three-dimensional structures of chikungunya E1, E2, and E3 monomers by ribbon model were obtained from the Protein Data Bank (ID code 3N41) [16]. The domains are color coded as follows: Domain I of E1 (dark red), domain II of E1 (dark yellow), domain III of E1 (dark blue), the FL region of E1 (orange), domain A of E2 (blue–green), domain B of E2 (dark green), domain C of E2 (pink), the arch region of E2 (purple), and E3 (gray). Mutated residues are depicted as a space-filling model: H456 (red), E572 (magenta), P1113 (light green), N1158 (light blue), and sugar-binding residues (gray). Yellow in space-filling model shows the immunodominant site. This figure was prepared by Molecular Operating Environment (Chemical Computing Group Inc) (Color figure online)

Table 1

Novel amino acid substitutions identified in the 56 chikungunya virus (CHIKV) clones derived from 7 patients

Clinical isolatesRegionPolypeptide positiona Protein positionb 2008-2009 Thai outbreak strainAmino acid substitution
CP13-2E2456131HY
CP16-4E2572247EA
CP7-6E11,113304PL
CP16 (all clones)E11,158349NI

a, bPolypeptide and protein positions are in accordance with the published sequence of CHIKV complete genome (GenBank Accession no. AF369024.2)

a Phylogenetic tree showing the relationships between the structural genes of different chikungunya virus (CHIKV) strains. The information was obtained from 56 clones derived from 7 infected patients in Ratchaburi Province of Thailand in 2010. The numbers below or above the branch nodes represent the neighbor-joining bootstrap values. Analysis was based on the nucleotide sequences of the structural genes using the MEGA 5.05 program and the maximum likelihood method based on 1,000 bootstrap replications. The 2010 isolates are denoted by black circles and bold type. Scale bars indicate 0.02 nucleotide substitutions per site. GenBank Accession numbers for all isolates were recorded. GenBank Accession nos: CP1 (AB857730–AB857737); CP7 (AB857738–AB857745); CP9 (AB857746–AB857753); CP10 (AB857754–AB857761); CP11 (AB857762–AB857769); CP13 (AB857770–AB857777); and CP16 (AB857778–AB857785), b Three-dimensional structures of chikungunya E1, E2, and E3 monomers by ribbon model were obtained from the Protein Data Bank (ID code 3N41) [16]. The domains are color coded as follows: Domain I of E1 (dark red), domain II of E1 (dark yellow), domain III of E1 (dark blue), the FL region of E1 (orange), domain A of E2 (blue–green), domain B of E2 (dark green), domain C of E2 (pink), the arch region of E2 (purple), and E3 (gray). Mutated residues are depicted as a space-filling model: H456 (red), E572 (magenta), P1113 (light green), N1158 (light blue), and sugar-binding residues (gray). Yellow in space-filling model shows the immunodominant site. This figure was prepared by Molecular Operating Environment (Chemical Computing Group Inc) (Color figure online) Novel amino acid substitutions identified in the 56 chikungunya virus (CHIKV) clones derived from 7 patients a, bPolypeptide and protein positions are in accordance with the published sequence of CHIKV complete genome (GenBank Accession no. AF369024.2) In conclusion, we isolated CHIKV derived from CHIKF-suspected patients in Ratchaburi Province of Thailand in 2010, and we report that CHIKV shows different characteristics when cultured in C6/36 cells, although it is not clear whether this is owing to the amino acid substitutions in the structural genes. Furthermore, CHIKV quasispecies are present in the Thai isolates from 2010, which include the clones harboring unique amino acid substitutions close to the immunodominant site (Fig. 1b) [16]. However, as we cannot rule out the possibility of antigenic escape mutants, further analysis is required. If we anticipate new outbreaks of chikungunya in Thailand, then we must increase CHIKV surveillance in disease-epidemic areas and deal with local outbreaks more effectively. Further studies of CHIKV isolated from either mosquitoes or chikungunya patients are needed. Below is the link to the electronic supplementary material. Supplementary material 1 (TIFF 1491 kb) Supplementary material 2 (DOCX 11 kb)
  14 in total

1.  Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography.

Authors:  James E Voss; Marie-Christine Vaney; Stéphane Duquerroy; Clemens Vonrhein; Christine Girard-Blanc; Elodie Crublet; Andrew Thompson; Gérard Bricogne; Félix A Rey
Journal:  Nature       Date:  2010-12-02       Impact factor: 49.962

2.  Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses.

Authors:  Boris Pastorino; Maël Bessaud; Marc Grandadam; Severine Murri; Hugues J Tolou; Christophe N Peyrefitte
Journal:  J Virol Methods       Date:  2004-12-15       Impact factor: 2.014

3.  Chikungunya virus and the mosquito vector Aedes aegypti in New Caledonia (South Pacific Region).

Authors:  Myrielle Dupont-Rouzeyrol; Valérie Caro; Laurent Guillaumot; Marie Vazeille; Eric D'Ortenzio; Jean-Michel Thiberge; Noémie Baroux; Ann-Claire Gourinat; Marc Grandadam; Anna-Bella Failloux
Journal:  Vector Borne Zoonotic Dis       Date:  2012-11-20       Impact factor: 2.133

Review 4.  Chikungunya fever: an epidemiological review of a re-emerging infectious disease.

Authors:  J Erin Staples; Robert F Breiman; Ann M Powers
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

Review 5.  Chikungunya in Southeast Asia: understanding the emergence and finding solutions.

Authors:  Rojjanaporn Pulmanausahakul; Sittiruk Roytrakul; Prasert Auewarakul; Duncan R Smith
Journal:  Int J Infect Dis       Date:  2011-07-19       Impact factor: 3.623

6.  An outbreak of chikungunya in southern Thailand from 2008 to 2009 caused by African strains with A226V mutation.

Authors:  Pornpimol Rianthavorn; Kesmanee Prianantathavorn; Norra Wuttirattanakowit; Apiradee Theamboonlers; Yong Poovorawan
Journal:  Int J Infect Dis       Date:  2010-04-22       Impact factor: 3.623

7.  Infection with chikungunya virus in Italy: an outbreak in a temperate region.

Authors:  G Rezza; L Nicoletti; R Angelini; R Romi; A C Finarelli; M Panning; P Cordioli; C Fortuna; S Boros; F Magurano; G Silvi; P Angelini; M Dottori; M G Ciufolini; G C Majori; A Cassone
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

8.  Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus.

Authors:  Marie Vazeille; Sara Moutailler; Daniel Coudrier; Claudine Rousseaux; Huot Khun; Michel Huerre; Julien Thiria; Jean-Sébastien Dehecq; Didier Fontenille; Isabelle Schuffenecker; Philippe Despres; Anna-Bella Failloux
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

9.  Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes.

Authors:  Konstantin A Tsetsarkin; Charles E McGee; Sara M Volk; Dana L Vanlandingham; Scott C Weaver; Stephen Higgs
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

10.  A single mutation in chikungunya virus affects vector specificity and epidemic potential.

Authors:  Konstantin A Tsetsarkin; Dana L Vanlandingham; Charles E McGee; Stephen Higgs
Journal:  PLoS Pathog       Date:  2007-12       Impact factor: 6.823

View more
  9 in total

1.  Neutralization activity of patient sera collected during the 2008-2009 Chikungunya outbreak in Thailand.

Authors:  Natsuko Kishishita; Mikiko Sasayama; Naokazu Takeda; Areerat Sa-Ngasang; Atchareeya Anuegoonpipat; Surapee Anantapreecha
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

2.  Detection of chikungunya virus antigen by a novel rapid immunochromatographic test.

Authors:  Tamaki Okabayashi; Tadahiro Sasaki; Promsin Masrinoul; Nantarat Chantawat; Sutee Yoksan; Narong Nitatpattana; Sarunyou Chusri; Ronald E Morales Vargas; Marc Grandadam; Paul T Brey; Soegeng Soegijanto; Kris Cahyo Mulyantno; Siti Churrotin; Tomohiro Kotaki; Oumar Faye; Ousmane Faye; Abdourahmane Sow; Amadou Alpha Sall; Orapim Puiprom; Panjaporn Chaichana; Takeshi Kurosu; Seiji Kato; Mieko Kosaka; Pongrama Ramasoota; Kazuyoshi Ikuta
Journal:  J Clin Microbiol       Date:  2014-11-19       Impact factor: 5.948

3.  Interepidemic Detection of Chikungunya Virus Infection and Transmission in Northeastern Thailand.

Authors:  Bao Chi Thi Le; Tipaya Ekalaksananan; Kesorn Thaewnongiew; Supranee Phanthanawiboon; Sirinart Aromseree; Thipruethai Phanitchat; Jureeporn Chuerduangphui; Apiporn T Suwannatrai; Neal Alexander; Hans J Overgaard; Michael J Bangs; Chamsai Pientong
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

4.  Promising application of monoclonal antibody against chikungunya virus E1-antigen across genotypes in immunochromatographic rapid diagnostic tests.

Authors:  Keita Suzuki; Ralph Huits; Juthamas Phadungsombat; Aekkachai Tuekprakhon; Emi E Nakayama; Riemsdijk van den Berg; Barbara Barbé; Lieselotte Cnops; Rummana Rahim; Abu Hasan; Hisahiko Iwamoto; Pornsawan Leaungwutiwong; Marjan van Esbroeck; Mizanur Rahman; Tatsuo Shioda
Journal:  Virol J       Date:  2020-07-02       Impact factor: 4.099

5.  Antibodies for Venezuelan Equine Encephalitis Virus Protect Embryoid Bodies from Chikungunya Virus.

Authors:  Emily M Schultz; TyAnthony J Jones; Kelli L Barr
Journal:  Viruses       Date:  2020-02-27       Impact factor: 5.048

6.  Antiviral Phosphorodiamidate Morpholino Oligomers are Protective against Chikungunya Virus Infection on Cell-based and Murine Models.

Authors:  Shirley Lam; Huixin Chen; Caiyun Karen Chen; Nyo Min; Justin Jang Hann Chu
Journal:  Sci Rep       Date:  2015-07-30       Impact factor: 4.379

7.  Variation at position 350 in the Chikungunya virus 6K-E1 protein determines the sensitivity of detection in a rapid E1-antigen test.

Authors:  Aekkachai Tuekprakhon; Emi E Nakayama; Koen Bartholomeeusen; Orapim Puiprom; Tadahiro Sasaki; Ralph Huits; Natthanej Luplertlop; Nathamon Kosoltanapiwat; Pannamas Maneekan; Kevin K Ariën; Tatsuo Shioda; Pornsawan Leaungwutiwong
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

8.  A Novel Sub-Lineage of Chikungunya Virus East/Central/South African Genotype Indian Ocean Lineage Caused Sequential Outbreaks in Bangladesh and Thailand.

Authors:  Juthamas Phadungsombat; Hisham Imad; Mizanur Rahman; Emi E Nakayama; Sajikapon Kludkleeb; Thitiya Ponam; Rummana Rahim; Abu Hasan; Kanaporn Poltep; Atsushi Yamanaka; Wasin Matsee; Watcharapong Piyaphanee; Weerapong Phumratanaprapin; Tatsuo Shioda
Journal:  Viruses       Date:  2020-11-17       Impact factor: 5.048

9.  Specialist laboratory networks as preparedness and response tool - the Emerging Viral Diseases-Expert Laboratory Network and the Chikungunya outbreak, Thailand, 2019.

Authors:  Giulietta Venturi; Stephan W Aberle; Tatjana Avšič-Županc; Luisa Barzon; Christoph Batejat; Elisa Burdino; Fabrizio Carletti; Rémi Charrel; Iva Christova; Jeff Connell; Victor Max Corman; Mary Emmanouil; Anne J Jääskeläinen; Ivan Kurolt; Yaniv Lustig; Miguel J Martinez; Marion Koopmans; Orsolya Nagy; Trung Nguyen; Anna Papa; Mercedes Pérez-Ruiz; Martin Pfeffer; Jelena Protic; Johan Reimerink; Giada Rossini; María Paz Sánchez-Seco Fariñas; Jonas Schmidt-Chanasit; Sandra Söderholm; Bertrand Sudre; Marjan Van Esbroeck; Chantal B Reusken
Journal:  Euro Surveill       Date:  2020-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.